Compare TransMedics Group Inc (TMDX) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs United Microelectronics Corp — how do they compare? TransMedics Group Inc trades at $87.9 (market cap $3.10B), while United Microelectronics Corp trades at $19.38 (market cap $47.81B). The key difference: United Microelectronics Corp is far larger — about 15.4× TransMedics Group Inc's market cap, and United Microelectronics Corp pays a 2.12% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | UMC | |
|---|---|---|
Market Cap | $3.10B | $47.81B |
Sector | Technology | Technology |
52-Week High | $150.42 | $28.02 |
52-Week Low | $61.99 | $6.58 |
Enterprise Value | $3.49B | $44.93B |
Dividend Yield | — | 2.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
UMC trades at $19.50, up 3.78% today, with neutral technical signals and strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.54 significantly exceeding the $0.16 expectation. Recent announcements include fab expansions in Singapore and Taiwan to meet AI-driven demand, supported by growing silicon photonics production. Valuation metrics show a P/E of 18.55 and P/S of 6.02, with robust profitability margins including 32.75% net income margin.
Outlook remains positive with projected revenue growth to $250.7B in 2026 and net income rebound to $82.1B. Key risks include semiconductor cycle volatility and execution challenges from capacity expansion. Analyst consensus shows mixed sentiment with 26.7% buy ratings versus 20% sell recommendations, suggesting cautious optimism amid expansion initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
